Quantifying uncertainty in long-term care costs following introduction of new drug therapy: the impo...
Download
1 / 10

Paul McNamee, Alessandra Vanoli, Debbie Hutchings, Ian McKeith, John Bond - PowerPoint PPT Presentation


  • 134 Views
  • Uploaded on

Quantifying uncertainty in long-term care costs following introduction of new drug therapy: the importance of model choice. Paul McNamee, Alessandra Vanoli, Debbie Hutchings, Ian McKeith, John Bond. In the next 25 minutes. Aims, methods and results of the paper

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about ' Paul McNamee, Alessandra Vanoli, Debbie Hutchings, Ian McKeith, John Bond' - calvin-fischer


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

Quantifying uncertainty in long-term care costs following introduction of new drug therapy: the importance of model choice

Paul McNamee, Alessandra Vanoli, Debbie Hutchings, Ian McKeith, John Bond


In the next 25 minutes
In the next 25 minutes... introduction of new drug therapy: the importance of model choice

  • Aims, methods and results of the paper

  • Conclusions and points for discussion


Aims of the paper
Aims of the paper introduction of new drug therapy: the importance of model choice

  • To compare two approaches in modelling the net NHS costs of drug treatment for Alzheimer’s Disease

  • Application of deterministic and probabilistic modelling methods to estimate costs and explore uncertainty about likely “budget impact” to the NHS over 10 years

  • Apply these methods to 3 different policies (ALL, NG1, NG2)


Some background
Some background introduction of new drug therapy: the importance of model choice

  • AD affects a large and growing number of older people

  • Drugs are effective at slowing disease progression

  • Uncertainty over whether they are ‘cost-effective’

  • NICE recommends assessment of “budget impact” for NHS, but only partially done for AD drugs in 2001

  • Recent guidance (March 05) - treatment should no longer be prescribed for new patients


Methods 1
Methods -1 introduction of new drug therapy: the importance of model choice

  • Simulate cost impact for AD population (England and Wales)

    • ONS population data

    • MRC ageing study for AD prevalence rates

    • Systematic review of effects of treatment on cognition

    • Long term prognosis from observational studies

  • OLS and GLM regression models estimate cost effect of changes in disease progression


Methods 2 regression models

Ordinary least squares (OLS) introduction of new drug therapy: the importance of model choice

Identity link

Normal (Gaussian) distribution

Generalized Linear Model (GLM)

Log link

Gamma or Negative Binomial Distribution

Methods – 2 Regression models

N=371

dependent variable: weekly cost

Constant term allowed.

independent variables: sex, age, ADL, MMSE




Conclusions
Conclusions £

  • Drug treatment for AD likely to lead to additional costs to the NHS

  • Choice of modelling method makes a difference to magnitude of estimates


Discussion points
Discussion points £

  • A GLM framework for probabilistic analysis more likely to produce outliers

  • Lack of evidence on long term effects

  • Estimates based on 10 year old observations of costs of care

  • Estimates assume full adoption for different NICE policy decisions – but how realistic?

  • How important is the “budget impact” question to local and national decision-makers?


ad